Potential role of gut microbiota in prostate cancer: immunity, metabolites, pathways of action?

The gut microbiota helps to reveal the relationship between diseases, but the role of gut microbiota in prostate cancer (PCa) is still unclear. Recent studies have found that the composition and abundance of specific gut microbiota are significantly different between PCa and non-PCa, and the gut microbiota may have common and unique characteristics between different diseases. Intestinal microorganisms are affected by various factors and interact with the host in a variety of ways. In the complex interaction model, the regulation of intestinal microbial metabolites and the host immune system is particularly important, and they play a key role in maintaining the ecological balance of intestinal microorganisms and metabolites. However, specific changes in the composition of intestinal microflora may promote intestinal mucosal immune imbalance, leading to the formation of tumors. Therefore, this review analyzes the immune regulation of intestinal flora and the production of metabolites, as well as their effects and mechanisms on tumors, and briefly summarizes that specific intestinal flora can play an indirect role in PCa through their metabolites, genes, immunity, and pharmacology, and directly participate in the occurrence, development, and treatment of tumors through bacterial and toxin translocation. We also discussed markers of high risk PCa for intestinal microbiota screening and the possibility of probiotic ingestion and fecal microbiota transplantation, in order to provide better treatment options for clinic patients. Finally, after summarizing a number of studies, we found that changes in immunity, metabolites.

[1]  B. Pottakkat,et al.  A Prospective Pilot Study , 2023 .

[2]  Alice Yu,et al.  Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome , 2022, Cancers.

[3]  Xiangming Mao,et al.  Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis , 2022, Microbiome.

[4]  X. Mao,et al.  Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis , 2022, Microbiome.

[5]  M. Catauro,et al.  Chemical Compounds of Berry-Derived Polyphenols and Their Effects on Gut Microbiota, Inflammation, and Cancer , 2022, Molecules.

[6]  P. Lin,et al.  Weight loss via a low-carbohydrate diet improved the intestinal permeability marker, zonulin, in prostate cancer patients , 2022, Annals of medicine.

[7]  S. Horie,et al.  Gut environment changes due to androgen deprivation therapy in patients with prostate cancer. , 2022, Prostate cancer and prostatic diseases.

[8]  G. Netto,et al.  High‐fat diet promotes prostate cancer growth through histamine signaling , 2022, International journal of cancer.

[9]  M. D. De Velasco,et al.  Gut microbiome and prostate cancer , 2022, International journal of urology : official journal of the Japanese Urological Association.

[10]  M. D. De Velasco,et al.  Connecting the Dots Between the Gut–IGF-1–Prostate Axis: A Role of IGF-1 in Prostate Carcinogenesis , 2022, Frontiers in Endocrinology.

[11]  N. Segata,et al.  Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer , 2022, Journal for ImmunoTherapy of Cancer.

[12]  S. Yachida,et al.  Firmicutes in Gut Microbiota Correlate with Blood Testosterone Levels in Elderly Men , 2022, The world journal of men's health.

[13]  T. Habuchi,et al.  Specific Gut Microbial Environment in Lard Diet-Induced Prostate Cancer Development and Progression , 2022, International journal of molecular sciences.

[14]  Z. Qian,et al.  Effects of Docetaxel Injection and Docetaxel Micelles on the Intestinal Barrier and Intestinal Microbiota , 2021, Advanced science.

[15]  M. Stampfer,et al.  Gut Microbiome–Dependent Metabolic Pathways and Risk of Lethal Prostate Cancer: Prospective Analysis of a PLCO Cancer Screening Trial Cohort , 2021, Cancer Epidemiology, Biomarkers & Prevention.

[16]  M. Ferrari,et al.  Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis , 2021, Science.

[17]  Yu-Chih Yang,et al.  Increase in Akkermansiaceae in Gut Microbiota of Prostate Cancer-Bearing Mice , 2021, International journal of molecular sciences.

[18]  D. Bhuyan,et al.  The complex interplay of gut microbiota with the five most common cancer types: From carcinogenesis to therapeutics to prognosis. , 2021, Critical reviews in oncology/hematology.

[19]  S. Pérez-Burillo,et al.  Green Tea and Its Relation to Human Gut Microbiome , 2021, Molecules.

[20]  Yufei Liu,et al.  Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways , 2021, Frontiers in Oncology.

[21]  O. Kepp,et al.  IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms , 2021, Journal for ImmunoTherapy of Cancer.

[22]  S. Yachida,et al.  The gut microbiota associated with high‐Gleason prostate cancer , 2021, Cancer Science.

[23]  G. Netto,et al.  Gut Microbiota–Derived Short-Chain Fatty Acids Promote Prostate Cancer Growth via IGF1 Signaling , 2021, Cancer Research.

[24]  M. Sohrabi,et al.  Role of microbiota-derived short-chain fatty acids in cancer development and prevention. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  S. Wong,et al.  A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy , 2021, Prostate Cancer and Prostatic Diseases.

[26]  M. Słojewski,et al.  Alterations in fecal short chain fatty acids (SCFAs) and branched short-chain fatty acids (BCFAs) in men with benign prostatic hyperplasia (BPH) and metabolic syndrome (MetS) , 2021, Aging.

[27]  W. Demark-Wahnefried,et al.  Gut microbial differences in breast and prostate cancer cases from two randomised controlled trials compared to matched cancer-free controls. , 2021, Beneficial microbes.

[28]  C. Woelk,et al.  Modulating gut microbiota to treat cancer , 2021, Science.

[29]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[30]  L. De Cecco,et al.  Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer , 2021, Cancer Research.

[31]  J. Lyu,et al.  Gut microbiome analysis as a predictive marker for the gastric cancer patients , 2021, Applied Microbiology and Biotechnology.

[32]  M. Creta,et al.  Escherichia coli Nissle 1917 as adjuvant therapy in patients with chronic bacterial prostatitis: a non-blinded, randomized, controlled trial , 2020, World Journal of Urology.

[33]  N. Ajami,et al.  Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients , 2020, Science.

[34]  Yan-hua Wang Current progress of research on intestinal bacterial translocation. , 2020, Microbial pathogenesis.

[35]  G. Reid,et al.  Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients , 2020, Nature Communications.

[36]  J. Wang-Rodriguez,et al.  Influence of Intratumor Microbiome on Clinical Outcome and Immune Processes in Prostate Cancer , 2020, Cancers.

[37]  Jian Yang,et al.  The interplay between host genetics and the gut microbiome reveals common and distinct microbiome features for complex human diseases , 2020, Microbiome.

[38]  M. Boccellino,et al.  The Crosstalk between Prostate Cancer and Microbiota Inflammation: Nutraceutical Products Are Useful to Balance This Interplay? , 2020, Nutrients.

[39]  S. Reynolds,et al.  The human microbiome and its link in prostate cancer risk and pathogenesis , 2020, Infectious agents and cancer.

[40]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[41]  Sumeed Syed Manzoor,et al.  The promise and challenge of cancer microbiome research , 2020, Genome Biology.

[42]  T. Lüscher,et al.  Therapeutic Implications , 2020, The Endothelium: Modulator of Cardiovascular Function.

[43]  M. Bielaszewska,et al.  Secretion and Delivery of Intestinal Pathogenic Escherichia coli Virulence Factors via Outer Membrane Vesicles , 2020, Frontiers in Cellular and Infection Microbiology.

[44]  Annah Lee,et al.  Microbiome and pathogen interaction with the immune system , 2020, Poultry science.

[45]  Oliver Fiehn,et al.  A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors , 2020, Cell.

[46]  N. Nonomura,et al.  Influence of Diet and Nutrition on Prostate Cancer , 2020, International journal of molecular sciences.

[47]  R. Schwabe,et al.  Gut microbiome in HCC - Mechanisms, diagnosis and therapy. , 2020, Journal of hepatology.

[48]  T. Powles,et al.  Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  Yufei Liu,et al.  Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer , 2020, Translational andrology and urology.

[50]  Matthew E. Hudson,et al.  Bacterial steroid-17,20-desmolase is a taxonomically rare enzymatic pathway that converts prednisone to 1,4-androstanediene-3,11,17-trione, a metabolite that causes proliferation of prostate cancer cells , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[51]  V. Mouraviev,et al.  The human gastrointestinal microbiota and prostate cancer development and treatment , 2019, Investigative and clinical urology.

[52]  David P Turner,et al.  Increased Preoperative Plasma Level of Microbial 16S rDNA Translocation Is Associated With Relapse After Prostatectomy in Prostate Cancer Patients , 2020, Frontiers in Oncology.

[53]  T. Key,et al.  Hormone‐related diseases and prostate cancer: An English national record linkage study , 2019, International journal of cancer.

[54]  X. Xia,et al.  Bacterial translocation in acute pancreatitis , 2019, Critical reviews in microbiology.

[55]  F. Boccardo,et al.  Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer , 2019, Cancers.

[56]  A. Hansen,et al.  The microbiome and cancer for clinicians. , 2019, Critical reviews in oncology/hematology.

[57]  H. Tilg,et al.  The intestinal microbiota fuelling metabolic inflammation , 2019, Nature Reviews Immunology.

[58]  A. Zaniboni,et al.  Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies , 2019, Cancers.

[59]  Christine B. Peterson,et al.  Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes , 2019, Cell.

[60]  Seong-Ah Kim,et al.  Serum level of sex steroid hormone is associated with diversity and profiles of human gut microbiome. , 2019, Research in microbiology.

[61]  Yufei Liu,et al.  High dietary fat intake lowers serum equol concentration and promotes prostate carcinogenesis in a transgenic mouse prostate model , 2019, Nutrition & Metabolism.

[62]  Yufei Liu,et al.  Combined maternal and post‐weaning high fat diet inhibits male offspring's prostate cancer tumorigenesis in transgenic adenocarcinoma of mouse prostate model , 2019, The Prostate.

[63]  R. Montironi,et al.  Microbiome and Cancers, With Focus on Genitourinary Tumors , 2019, Front. Oncol..

[64]  Y. Chan,et al.  Gut microbial dysbiosis is associated with allergen-specific IgE responses in young children with airway allergies , 2019, The World Allergy Organization journal.

[65]  T. Spector,et al.  Interplay between the human gut microbiome and host metabolism , 2019, Nature Communications.

[66]  Robert W. Li,et al.  Inhibition of Tumor Growth by Dietary Indole-3-Carbinol in a Prostate Cancer Xenograft Model May Be Associated with Disrupted Gut Microbial Interactions , 2019, Nutrients.

[67]  G. Banna,et al.  Gut Microbiota and Cancer: From Pathogenesis to Therapy , 2019, Cancers.

[68]  C. Sears,et al.  Roles for Interleukin 17 and Adaptive Immunity in Pathogenesis of Colorectal Cancer. , 2018, Gastroenterology.

[69]  J. Vanamala,et al.  Causal Relationship between Diet-Induced Gut Microbiota Changes and Diabetes: A Novel Strategy to Transplant Faecalibacterium prausnitzii in Preventing Diabetes , 2018, International journal of molecular sciences.

[70]  D. Ankerst,et al.  Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer. , 2018, European urology.

[71]  J. Marchesi,et al.  Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment , 2018, Ecancermedicalscience.

[72]  J. Raes,et al.  Regional variation limits applications of healthy gut microbiome reference ranges and disease models , 2018, Nature Medicine.

[73]  G. Prins,et al.  Estrogens and prostate cancer , 2018, Prostate Cancer and Prostatic Diseases.

[74]  K. Pienta,et al.  Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies , 2018, Prostate Cancer and Prostatic Diseases.

[75]  Sabita Roy,et al.  Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response. , 2018, Gastroenterology.

[76]  T. Spector,et al.  Role of the gut microbiota in nutrition and health , 2018, British Medical Journal.

[77]  A. Kurilshikov,et al.  Environment dominates over host genetics in shaping human gut microbiota , 2018, Nature.

[78]  G. Castoria,et al.  Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications , 2018, Front. Oncol..

[79]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[80]  N. Nonomura,et al.  A novel model to predict positive prostate biopsy based on serum androgen level , 2017, Endocrine-related cancer.

[81]  G. Hunter,et al.  Dietary Changes Impact the Gut Microbe Composition in Overweight and Obese Men with Prostate Cancer Undergoing Radical Prostatectomy. , 2016, Journal of the Academy of Nutrition and Dietetics.

[82]  C. Huttenhower,et al.  The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: A Prospective, Pilot Study. , 2018, Urology.

[83]  W. Nelson,et al.  The inflammatory microenvironment and microbiome in prostate cancer development , 2018, Nature Reviews Urology.

[84]  Jun Yu,et al.  Gavage of Fecal Samples From Patients With Colorectal Cancer Promotes Intestinal Carcinogenesis in Germ-Free and Conventional Mice. , 2017, Gastroenterology.

[85]  R. Chapkin,et al.  Shaping functional gut microbiota using dietary bioactives to reduce colon cancer risk. , 2017, Seminars in cancer biology.

[86]  H. Pommergaard,et al.  Linking Gut Microbiota to Colorectal Cancer , 2017, Journal of Cancer.

[87]  J. Arthur,et al.  The microbiome and the hallmarks of cancer , 2017, PLoS pathogens.

[88]  H. Yadav,et al.  Bacterial Translocation from the Gut to the Distant Organs: An Overview , 2017, Annals of Nutrition and Metabolism.

[89]  N. Segata,et al.  Shotgun metagenomics, from sampling to analysis , 2017, Nature Biotechnology.

[90]  M. Estes,et al.  Role for FimH in Extraintestinal Pathogenic Escherichia coli Invasion and Translocation through the Intestinal Epithelium , 2017, Infection and Immunity.

[91]  S. Montain,et al.  Changes in intestinal microbiota composition and metabolism coincide with increased intestinal permeability in young adults under prolonged physiological stress. , 2017, American journal of physiology. Gastrointestinal and liver physiology.

[92]  A. Iwama,et al.  Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity. , 2017, Cancer discovery.

[93]  S. Roy,et al.  Microbes and Cancer. , 2017, Annual review of immunology.

[94]  Y. Belkaid,et al.  Homeostatic Immunity and the Microbiota. , 2017, Immunity.

[95]  K. McCoy,et al.  Regionalized Development and Maintenance of the Intestinal Adaptive Immune Landscape. , 2017, Immunity.

[96]  Ian D. Wilson,et al.  Gut microbiota modulation of chemotherapy efficacy and toxicity , 2017, Nature Reviews Gastroenterology &Hepatology.

[97]  D. Antonopoulos,et al.  Interleukin-15 promotes intestinal dysbiosis with butyrate deficiency associated with increased susceptibility to colitis , 2016, The ISME Journal.

[98]  S. Bischoff,et al.  Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese individuals undergoing weight reduction. , 2016, The American journal of clinical nutrition.

[99]  Sumio Watanabe,et al.  Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis , 2017, Inflammatory bowel diseases.

[100]  T. Rebbeck Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography. , 2017, Seminars in radiation oncology.

[101]  S. Lynch,et al.  The Human Intestinal Microbiome in Health and Disease. , 2016, The New England journal of medicine.

[102]  J. Sung,et al.  Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. , 2016, European urology.

[103]  P. Rosenstiel,et al.  Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. , 2016, Immunity.

[104]  F. Bäckhed,et al.  Signals from the gut microbiota to distant organs in physiology and disease , 2016, Nature Medicine.

[105]  D. Holtzman,et al.  Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease , 2016, Scientific Reports.

[106]  T. Dinan,et al.  Gut microbiota, obesity and diabetes , 2016, Postgraduate Medical Journal.

[107]  Dudley Lamming,et al.  High fat diet enhances stemness and tumorigenicity of intestinal progenitors , 2016, Nature.

[108]  M. Edmond,et al.  Understanding Luminal Microorganisms and Their Potential Effectiveness in Treating Intestinal Inflammation , 2016, Inflammatory bowel diseases.

[109]  V. Rossi,et al.  Prostate cancer stem cells: the role of androgen and estrogen receptors , 2015, Oncotarget.

[110]  T. R. Licht,et al.  Antibiotic Treatment Affects Intestinal Permeability and Gut Microbial Composition in Wistar Rats Dependent on Antibiotic Class , 2015, PloS one.

[111]  Jason B. Williams,et al.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.

[112]  Kevin Haynes,et al.  Recurrent antibiotic exposure may promote cancer formation--Another step in understanding the role of the human microbiota? , 2015, European journal of cancer.

[113]  Qiang Feng,et al.  Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer , 2015, Gut.

[114]  Na-Ri Shin,et al.  Proteobacteria: microbial signature of dysbiosis in gut microbiota. , 2015, Trends in biotechnology.

[115]  Gabriel A. Al-Ghalith,et al.  Chemotherapy‐driven dysbiosis in the intestinal microbiome , 2015, Alimentary pharmacology & therapeutics.

[116]  J. Balzarini,et al.  Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs , 2015, FEBS open bio.

[117]  Nobhojit Roy,et al.  The Global Burden of Cancer 2013. , 2015, JAMA oncology.

[118]  Justine W. Debelius,et al.  Microbial endocrinology: the interplay between the microbiota and the endocrine system. , 2015, FEMS microbiology reviews.

[119]  Myung-Shik Lee,et al.  Gut Microbiota and Metabolic Disorders , 2015, Diabetes & metabolism journal.

[120]  U. Das,et al.  Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia , 2015, Archives of medical science : AMS.

[121]  Xuewu Zhang,et al.  Effects of cyclophosphamide on immune system and gut microbiota in mice. , 2015, Microbiological research.

[122]  K. Svenson,et al.  Diet dominates host genotype in shaping the murine gut microbiota. , 2015, Cell host & microbe.

[123]  M. Conlon,et al.  The Impact of Diet and Lifestyle on Gut Microbiota and Human Health , 2014, Nutrients.

[124]  G. Gao,et al.  Influenza viral neuraminidase primes bacterial coinfection through TGF-β–mediated expression of host cell receptors , 2014, Proceedings of the National Academy of Sciences.

[125]  A. Zoubeidi,et al.  Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review). , 2014, International journal of oncology.

[126]  Nengwang Yu,et al.  Mysteries of TGF-β Paradox in Benign and Malignant Cells , 2014, Front. Oncol..

[127]  M. Kleinewietfeld,et al.  Gut Microbiota and the Paradox of Cancer Immunotherapy , 2014, Front. Immunol..

[128]  Y. Belkaid,et al.  Role of the Microbiota in Immunity and Inflammation , 2014, Cell.

[129]  G. Dalmasso,et al.  Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype , 2014, Gut.

[130]  Wancai Yang,et al.  Soy isoflavones and prostate cancer: A review of molecular mechanisms , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[131]  S. Bultman,et al.  Emerging roles of the microbiome in cancer. , 2014, Carcinogenesis.

[132]  E. Alm,et al.  Probiotic Microbes Sustain Youthful Serum Testosterone Levels and Testicular Size in Aging Mice , 2014, PloS one.

[133]  Z. Culig,et al.  Androgen receptor signaling in prostate cancer , 2014, Cancer and Metastasis Reviews.

[134]  V. Ganapathy,et al.  Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the host. , 2013, Current opinion in pharmacology.

[135]  Yuzhuo Wang,et al.  Genistein versus ICI 182, 780: An ally or enemy in metastatic progression of prostate cancer , 2013, The Prostate.

[136]  F. Marincola,et al.  Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment , 2013, Science.

[137]  Eric Vivier,et al.  The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide , 2013, Science.

[138]  R. Schwabe,et al.  The Microbiome and Cancer , 2021, Gut Feelings.

[139]  M. R. Rubinstein,et al.  Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. , 2013, Cell host & microbe.

[140]  A. Tsujimura The Relationship between Testosterone Deficiency and Men's Health , 2013, The world journal of men's health.

[141]  D. Hackam,et al.  Mechanisms of gut barrier failure in the pathogenesis of necrotizing enterocolitis: Toll-like receptors throw the switch. , 2013, Seminars in pediatric surgery.

[142]  Valesca Anschau,et al.  Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer , 2013, Prostate cancer.

[143]  N. Nonomura,et al.  Inflammation and prostate carcinogenesis , 2013, International journal of urology : official journal of the Japanese Urological Association.

[144]  K. Brown,et al.  Diet-Induced Dysbiosis of the Intestinal Microbiota and the Effects on Immunity and Disease , 2012, Nutrients.

[145]  A. Macpherson,et al.  Interactions Between the Microbiota and the Immune System , 2012, Science.

[146]  H. Akaza Prostate cancer chemoprevention by soy isoflavones: Role of intestinal bacteria as the “second human genome” , 2012, Cancer science.

[147]  Katherine H. Huang,et al.  Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.

[148]  E. Giovannucci,et al.  Lifestyle and dietary factors in the prevention of lethal prostate cancer. , 2012, Asian journal of andrology.

[149]  V. Adhami,et al.  Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model. , 2012, Carcinogenesis.

[150]  A. D. De Marzo,et al.  Prostate cancer and inflammation: the evidence , 2012, Histopathology.

[151]  J. Bakken,et al.  Treating Clostridium difficile infection with fecal microbiota transplantation. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[152]  M. Blaser,et al.  Microbiome and malignancy. , 2011, Cell host & microbe.

[153]  M. Poutanen,et al.  A single dose of enterolactone activates estrogen signaling and regulates expression of circadian clock genes in mice. , 2011, The Journal of nutrition.

[154]  C. McClain,et al.  Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. , 2011, JPEN. Journal of parenteral and enteral nutrition.

[155]  A. Malik,et al.  Influence of ellagic acid on prostate cancer cell proliferation: a caspase-dependent pathway. , 2011, Asian Pacific journal of tropical medicine.

[156]  Fiona Powrie,et al.  Intestinal homeostasis and its breakdown in inflammatory bowel disease , 2011, Nature.

[157]  Clara Abraham,et al.  Interactions between the host innate immune system and microbes in inflammatory bowel disease. , 2011, Gastroenterology.

[158]  G. Prins,et al.  Estrogen action and prostate cancer , 2011, Expert review of endocrinology & metabolism.

[159]  V. Adhami,et al.  Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[160]  B. Finlay,et al.  Antibiotic Treatment Alters the Colonic Mucus Layer and Predisposes the Host to Exacerbated Citrobacter rodentium-Induced Colitis , 2011, Infection and Immunity.

[161]  S. Raimondi,et al.  Folate Production by Probiotic Bacteria , 2011, Nutrients.

[162]  Y. Okamoto,et al.  Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde. , 2011, American journal of cancer research.

[163]  E. Deitch,et al.  Gut lymph and lymphatics: a source of factors leading to organ injury and dysfunction , 2010, Annals of the New York Academy of Sciences.

[164]  C. Jobin,et al.  High-Fat Diet: Bacteria Interactions Promote Intestinal Inflammation Which Precedes and Correlates with Obesity and Insulin Resistance in Mouse , 2010, PloS one.

[165]  C. Coopersmith,et al.  Can we protect the gut in critical illness? The role of growth factors and other novel approaches. , 2010, Critical care clinics.

[166]  Y. Bignon,et al.  Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by polymerase chain reaction arrays in human prostate cancer cell lines. , 2010, Cancer epidemiology.

[167]  J. Gordon,et al.  Homeostasis and Inflammation in the Intestine , 2010, Cell.

[168]  N. Miyanaga,et al.  Isolation and characterization of the equol-producing bacterium Slackia sp. strain NATTS , 2010, Archives of Microbiology.

[169]  Tatsushi Yoshida,et al.  Lactobacillus strains induce TRAIL production and facilitate natural killer activity against cancer cells , 2010, FEBS letters.

[170]  Jeffrey N. Weiser,et al.  Recognition of Peptidoglycan from the Microbiota by Nod1 Enhances Systemic Innate Immunity , 2010, Nature Medicine.

[171]  R. Knight,et al.  The Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice , 2009, Science Translational Medicine.

[172]  D. Ferreira,et al.  Effects of pomegranate chemical constituents/intestinal microbial metabolites on CYP1B1 in 22Rv1 prostate cancer cells. , 2009, Journal of agricultural and food chemistry.

[173]  P. Qian,et al.  Conservative Fragments in Bacterial 16S rRNA Genes and Primer Design for 16S Ribosomal DNA Amplicons in Metagenomic Studies , 2009, PloS one.

[174]  N. Miyanaga,et al.  Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers , 2009, Prostate Cancer and Prostatic Diseases.

[175]  J. Baron,et al.  Folic acid and risk of prostate cancer: results from a randomized clinical trial. , 2009, Journal of the National Cancer Institute.

[176]  M. Inoue,et al.  Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: the Japan Public Health Center. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[177]  K. Shida,et al.  Probiotics and immunology: separating the wheat from the chaff. , 2008, Trends in immunology.

[178]  B. Kelsall Recent progress in understanding the phenotype and function of intestinal dendritic cells and macrophages , 2008, Mucosal Immunology.

[179]  B. Henderson,et al.  Legume and isoflavone intake and prostate cancer risk: The Multiethnic Cohort Study , 2008, International journal of cancer.

[180]  F. Powrie,et al.  Dendritic cells in intestinal immune regulation , 2008, Nature Reviews Immunology.

[181]  R. Bibiloni,et al.  Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet–Induced Obesity and Diabetes in Mice , 2008, Diabetes.

[182]  M. Clynes,et al.  CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance , 2008, British Journal of Cancer.

[183]  Manami Inoue,et al.  Green tea consumption and prostate cancer risk in Japanese men: a prospective study. , 2007, American journal of epidemiology.

[184]  Z. Ourabah,et al.  RESULTS OF A RANDOMIZED CLINICAL TRIAL , 2008 .

[185]  R. Feinman,et al.  Intravenous Injection of Trauma-Hemorrhagic Shock Mesenteric Lymph Causes Lung Injury That Is Dependent Upon Activation of the Inducible Nitric Oxide Synthase Pathway , 2007, Annals of surgery.

[186]  Jun Wang,et al.  Epigallocatechin‐3‐Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: Mechanisms of action , 2007, The Prostate.

[187]  Marc A Suchard,et al.  Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. , 2007, Journal of agricultural and food chemistry.

[188]  K. McCoy,et al.  Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. , 2007, Seminars in immunology.

[189]  B. Zilberstein,et al.  Bacterial translocation: Overview of mechanisms and clinical impact , 2007, Journal of gastroenterology and hepatology.

[190]  H. Adlercreutz Lignans and Human Health , 2007, Critical reviews in clinical laboratory sciences.

[191]  Xiaomei Ma,et al.  Global Burden of Cancer , 2006, The Yale journal of biology and medicine.

[192]  S. Mertens-Talcott,et al.  Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers. , 2006, Journal of agricultural and food chemistry.

[193]  David Heber,et al.  Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. , 2006, The Journal of nutrition.

[194]  C. Dejong,et al.  Strain-Specific Effects of Probiotics on Gut Barrier Integrity following Hemorrhagic Shock , 2005, Infection and Immunity.

[195]  F. Bäckhed,et al.  Host-Bacterial Mutualism in the Human Intestine , 2005, Science.

[196]  J. Lampe,et al.  Gut Bacterial Metabolism of the Soy Isoflavone Daidzein: Exploring the Relevance to Human Health , 2005, Experimental biology and medicine.

[197]  V. Adhami,et al.  Oral Consumption of Green Tea Polyphenols Inhibits Insulin-Like Growth Factor-I–Induced Signaling in an Autochthonous Mouse Model of Prostate Cancer , 2004, Cancer Research.

[198]  J. Sánchez-Payá,et al.  A Study of Intestinal Permeability in Relation to the Inflammatory Response and Plasma Endocab IgM Levels in Patients with Acute Pancreatitis , 2004, Journal of clinical gastroenterology.

[199]  Pascale Cossart,et al.  Bacterial Invasion: The Paradigms of Enteroinvasive Pathogens , 2004, Science.

[200]  B. Jacobsen,et al.  Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States) , 1998, Cancer Causes & Control.

[201]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[202]  R. Wiest,et al.  Bacterial translocation in the gut , 2003 .

[203]  B. Menzies,et al.  The role of fibronectin binding proteins in the pathogenesis of Staphylococcus aureus infections , 2003, Current opinion in infectious diseases.

[204]  R. Wiest,et al.  Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. , 2003, Best practice & research. Clinical gastroenterology.

[205]  A. Dignass,et al.  Intestinal barrier function , 2002, Current opinion in clinical nutrition and metabolic care.

[206]  Kazuyoshi Takeda,et al.  New aspects of natural-killer-cell surveillance and therapy of cancer , 2002, Nature Reviews Cancer.

[207]  Sang-Woon Choi,et al.  Folate status: effects on pathways of colorectal carcinogenesis. , 2002, The Journal of nutrition.

[208]  G. Hecht Microbes and microbial toxins: paradigms for microbial-mucosal interactions. VII. Enteropathogenic Escherichia coli: physiological alterations from an extracellular position. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[209]  W. Lencer Microbes and microbial Toxins: paradigms for microbial-mucosal toxins. V. Cholera: invasion of the intestinal epithelial barrier by a stably folded protein toxin. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[210]  L. Grande,et al.  Bacterial translocation of enteric organisms in patients with cirrhosis. , 2001, Journal of hepatology.

[211]  C. Pothoulakis Effects of Clostridium difficile Toxins on Epithelial Cell Barrier , 2000, Annals of the New York Academy of Sciences.

[212]  A. Fasano,et al.  Regulation of Intercellular Tight Junctions by Zonula Occludens Toxin and Its Eukaryotic Analogue Zonulin , 2000, Annals of the New York Academy of Sciences.

[213]  S. Erlandsen,et al.  Clostridium difficile toxins A and B can alter epithelial permeability and promote bacterial paracellular migration through HT-29 enterocytes. , 2000, Shock.

[214]  C. Sears,et al.  Molecular physiology and pathophysiology of tight junctions V. assault of the tight junction by enteric pathogens. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[215]  J. Alverdy,et al.  The key role of Pseudomonas aeruginosa PA-I lectin on experimental gut-derived sepsis. , 2000, Annals of surgery.

[216]  P. Sansonetti,et al.  Induction of Necrosis in Human Neutrophils byShigella flexneri Requires Type III Secretion, IpaB and IpaC Invasins, and Actin Polymerization , 2000, Infection and Immunity.

[217]  J. Stanford,et al.  Fruit and vegetable intakes and prostate cancer risk. , 2000, Journal of the National Cancer Institute.

[218]  M. Willingham,et al.  p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. , 1999, Cancer letters.

[219]  S. Akira,et al.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.

[220]  J. Nakayama,et al.  Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. , 1997, Cancer research.

[221]  T. Miller,et al.  Pathways of acetate, propionate, and butyrate formation by the human fecal microbial flora , 1996, Applied and environmental microbiology.

[222]  G. Simonian,et al.  A COMPARISON OF SURVIVAL AT DIFFERENT DEGREES OF HEMORRHAGIC SHOCK IN GERM-FREE AND GERM-BEARING RATS , 1995, Shock.

[223]  R. Berg,et al.  T lymphocytes in host defense against bacterial translocation from the gastrointestinal tract , 1994, Infection and immunity.

[224]  J. Alexander,et al.  Bacterial Translocation: A Potential Source for Infection in Acute Pancreatitis , 1993, Pancreas.

[225]  W. Thurston The evidence , 1985 .

[226]  Anton Berns,et al.  Separating the wheat from the chaff , 1991, Current Biology.

[227]  R. Berg,et al.  Translocation of indigenous bacteria from the gastrointestinal tract of mice after oral ricinoleic acid treatment. , 1986, Gastroenterology.

[228]  J. Marshall,et al.  Multiple-organ-failure syndrome. , 1986, Archives of surgery.

[229]  R. Berg,et al.  Relationship between cecal population levels of indigenous bacteria and translocation to the mesenteric lymph nodes , 1983, Infection and immunity.

[230]  S. Hamilton,et al.  Ischemic injury in the cat small intestine: Role of superoxide radicals , 1982 .

[231]  R. Berg Promotion of the translocation of enteric bacteria from the gastrointestinal tracts of mice by oral treatment with penicillin, clindamycin, or metronidazole , 1981, Infection and immunity.

[232]  R. Berg,et al.  Bacterial translocation from the gastrointestinal tract of athymic (nu/nu) mice , 1980, Infection and immunity.

[233]  B. Drasar,et al.  The relation between diet and the gut microflora in man , 1973, Proceedings of the Nutrition Society.

[234]  C. Lamanna,et al.  Translocation of microorganisms across the intestinal wall of the rat: effect of microbial size and concentration. , 1966, The Journal of infectious diseases.